Scientists tested 39 sweeteners and uncovered surprising gut effects - Science Daily
This story deserves to be shared
Send it to someone who'd care, or post it on your networks.
Common sweeteners may be doing much more inside our bodies than simply replacing sugar. Scientists at the University of Cambridge have discovered that many widely used sweeteners can directly interfere with the growth of gut bacteria, and their effects can become even more pronounced when combined with medications or other everyday substances.
In laboratory experiments involving 39 sweeteners and 25 species of gut bacteria, researchers found that roughly three-quarters of the sweeteners altered the growth of at least one bacterial species. Some slowed or completely stopped the growth of microbes associated with a healthy digestive system.
This article is an excerpt. To read the full content, visit the original source. Science Daily
Related articles
Scientists find a youth protein that helps aging brain cells act young again - Science Daily
A protein associated with youth may help aging brain cells regain some of their lost abilities. Scientists at the Icahn School of Medicine at Mount Sinai have discovered that TIMP2 plays an important role in keeping the brain's immune cells healthy, offering new clues about how the brain changes with age. In a study published in Nature Communications, researchers found that removing TIMP2 caused brain immune cells, known as microglia, to develop characteristics linked to aging and neurodegenerative disease. When the scientists restored TIMP2 in the bloodstream of older mice, these cells became better at removing cellular debris and showed fewer molecular signs of inflammation and other potentially harmful changes.
AJMC | Lymphoma outcomes hinge on oncology, not viral load in people with HIV - European AIDS Treatment Group
AJMC news storyOncologic factors, not HIV viral suppression status, determine how well people with HIV fare after a lymphoma diagnosis, according to a retrospective cohort study published in HIV Medicine. Lymphoma has remained one of the most common cancers in people with HIV since the earliest years of the epidemic, and that risk has persisted even as antiretroviral therapy (ART) transformed HIV from a fatal illness into a manageable chronic condition. A 2024 protocol published in BMJ Open, outlining a planned systematic review to quantify that excess burden worldwide, noted that people with AIDS face roughly 400 times the risk of high-grade non-Hodgkin lymphoma (NHL) and about 15 times the risk of low-grade NHL compared with the general population. Because ART has sharply reduced AIDS-defining malignancies, clinicians have debated whether virologic control should factor into how aggressively to treat a lymphoma, or whether oncologic staging and histology alone should drive therapy.
0 comments
No comments yet. Be the first to share your thoughts!